Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## Why UHC Denied a Checkpoint Inhibitor as Not FDA-Approved — and How to Appeal

UnitedHealthcare may issue a "not FDA-approved" denial for a checkpoint inhibitor — pembrolizumab (Keytruda), nivolumab (Opdivo), ipilimumab (Yervoy), atezolizumab (Tecentriq), durvalumab (Imfinzi), or cemiplimab (Libtayo) — when the specific use requested does not match an indication listed in UHC's coverage policy, even when the drug itself is FDA-approved for other uses or when the requested use is FDA-approved but not captured in UHC's policy due to a policy update lag. This denial can also arise when the requested use is an off-label application that is, however, supported by an approved compendia listing.

## Why This Denial Is Appealable

If the requested use is FDA-approved, this denial is directly rebutted by attaching the relevant section of the FDA prescribing information. If the use is off-label but supported by NCCN, Micromedex, or another approved compendia, many state laws and UHC's own policies require coverage of compendia-supported off-label uses for cancer. Off-label oncology use supported by an approved compendia is broadly recognized as a coverage obligation under state anti-discrimination laws and Medicare/Medicaid rules (where applicable). Under ACA §2719, you have the right to independent external review by a qualified oncologist.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice (typically 180 days for non-urgent). UHC must decide within 30 days for standard pre-service appeals.
• Expedited review: Request expedited internal and external review simultaneously if treatment delay is urgent — 72-hour decision requirement.
• External review (ACA §2719): If the internal appeal is denied, request independent external review. The reviewer evaluates whether UHC's determination was consistent with applicable law and accepted medical practice.
• Compendia-protection argument: Your attorney or patient advocate should research your state's compendia-coverage law. Many states require coverage of NCCN-listed off-label uses.
• State insurance department complaint: File simultaneously with your internal appeal.

## Documentation to Gather

• FDA prescribing information — indication section: Attach the exact FDA-approved indication for your tumor type, histology, biomarker, and line of therapy. If the use is FDA-approved, this document alone may be sufficient to overturn the denial.
• Companion diagnostic result: If the FDA approval is biomarker-gated, attach the lab report confirming the result meets the indication criteria stated in the FDA label.
• NCCN or compendia listing (if off-label): Your oncologist should identify and attach the applicable NCCN recommendation category for your tumor and regimen. Note the compendia edition and date.
• Oncologist letter of medical necessity: Explaining why this specific agent is FDA-approved or compendia-supported for your specific indication, and why it is medically necessary.
• Pathology and staging documentation: Confirming the tumor type, histology, and stage match the approved or compendia-listed indication.

## Criteria-Mapping Structure

| UHC Denial Basis | Your Documentation | |---|---| | Not FDA-approved for this indication | FDA label indication section (attached) | | Companion diagnostic not met | Lab report with result | | Not in approved compendia (if off-label) | NCCN listing + edition date | | Not consistent with accepted practice | Oncologist letter + guideline support | | Tumor type/histology mismatch | Pathology report |